Author Archives: admin


Stem Cell Clinic > Articles by: admin

23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test

By Global News Feed

Provides 23andMe+ Premium members with highly requested insight into their likelihood of developing slightly elevated homocysteine levels Provides 23andMe+ Premium members with highly requested insight into their likelihood of developing slightly elevated homocysteine levels

View post:
23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test

PharmAla Completes Shipment of LaNeo™ MDMA to the University of Washington    

By Global News Feed

TORONTO, March 21, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has successfully completed an international shipment of LaNeo™ MDMA to the University of Washington, USA. This continues the fulfillment of orders from important human research studies in the United States that have chosen to use Phamala’s pharmaceutical grade LaNeo™ MDMA capsules for their clinical research.

View original post here:
PharmAla Completes Shipment of LaNeo™ MDMA to the University of Washington    

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

By Global News Feed

SUNNYVALE, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2024 on Wednesday, March 26, 2025, and will host a corporate update conference call on Monday, March 31, 2025 (time and dial-information to be announced). The conference call will follow the presentation, “A Double-blind, Randomized Controlled Trial of an Autologous Cell Therapy in Patients with HFrEF: Principal Results from the CardiAMP-HF Trial,” at the American College of Cardiology 2025 Scientific Sessions in Chicago on March 30, 2025.

More here:
BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones

By Global News Feed

Vancouver, Canada, March 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that its innovative drug candidate, CMND-100, has arrived in the United States following successful manufacturing. This marks a key milestone as the Company prepares to initiate its FDA-approved Phase I/IIa clinical trial for the treatment of Alcohol Use Disorder (AUD), a condition affecting over 28 million adults in the U.S. alone.

See the original post:
Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones

Bright Green Corporation Announces the next steps for the completion of its restructuring plan

By Global News Feed

FORT LAUDERDALE, FLORIDA, March 21, 2025 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC: BGXX) (“Bright Green” or the “Company”) announced that on March 17, 2025, on behalf of the Company, Lynn Stockwell has asked the court to approve the “RSA” Restructuring Security Agreement, Disclosure Statement and Plan. The highlights of the Plan and Disclosure will provide new equity for the company to pay all creditors with approved claims in full, in addition the Company equity shareholders will retain their interests in the Company and are unimpaired with no dilution.

See the original post here:
Bright Green Corporation Announces the next steps for the completion of its restructuring plan

Impact Biomedical Inc. Announcement Stock Activity/Pricing

By Global News Feed

HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that there has been no material development in its business affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action regarding its share price.

Read the original:
Impact Biomedical Inc. Announcement Stock Activity/Pricing

→←